Revascularization Pretreated With Fingolimod in Acute Stroke
Status:
Not yet recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
Acute ischemic stroke (AIS) is a common type of stroke in the elderly. Timely blood flow
recovery can effectively improve the long-term prognosis of patients. According to five
large-scale multicenter randomized controlled trials (MR clean, swift-prime, revascat, escape
and extend-ia) in recent years, the effect of endovascular therapy (EVT) for acute anterior
circulation occlusion of great vessels is significantly better than that of drug therapy
alone. Therefore, for patients who meet the "Chinese guidelines for the diagnosis and
treatment of acute ischemic stroke" (2018 Edition), the effect of EVT is better than that of
drug therapy alone, Intravenous thrombolysis within 4.5 hours and endovascular mechanical
thrombectomy within 6 hours can effectively relieve the clinical symptoms and reduce the
mortality of AIS. However, due to the narrow application time window of intravenous
thrombolysis and mechanical thrombectomy, although the thrombectomy time window of some
eligible patients was relaxed to 24 hours after dawn and defuse3 and other related studies,
the reperfusion injury after the blocked cerebral artery recanalization has brought huge
obstacles to clinical application. Therefore, how to improve the prognosis of patients with
endovascular therapy has become a hot research direction.
Fingomod is a kind of sphingosine analogues acting on sphingosine-1-phosphate (sipr). After
phosphorylation in the body, fingomod combines with lymphocyte SIP receptor, changes
lymphocyte migration route, prevents it from entering the area outside the lymphoid tissue,
so as to avoid its infiltration into the central nervous system and achieve
immunosuppression. Currently, it is the first-line disease modifying oral drug for multiple
sclerosis. Fingolmod shows neuroprotective effects on many central nervous system diseases
including cerebral ischemia. Fingomod not only reduced the number of lymphocytes invading the
brain, but also decreased the number of lymphocytes in the microcirculation system
Phase:
N/A
Details
Lead Sponsor:
The Affiliated Hospital of Xuzhou Medical University